BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10636238)

  • 1. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
    Pascal Y; Andrianjara CR; Auclair E; Avenel N; Bertin B; Calvet A; Féru F; Lardon S; Moodley I; Ouagued M; Payne A; Pruniaux MP; Szilagyi C
    Bioorg Med Chem Lett; 2000 Jan; 10(1):35-8. PubMed ID: 10636238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
    Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
    Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aryl sulfonamides as selective PDE4 inhibitors.
    Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
    Hulme C; Moriarty K; Miller B; Mathew R; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Huang FC; Labaudiniere R; Djuric SW
    Bioorg Med Chem Lett; 1998 Jul; 8(14):1867-72. PubMed ID: 9873449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
    Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Kikkawa H; Ikezawa K; Naito K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2347-50. PubMed ID: 12824031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 8-Methoxyquinolines as PDE4 inhibitors.
    Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
    Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
    J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
    Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
    Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally active indole N-oxide PDE4 inhibitors.
    Hulme C; Mathew R; Moriarty K; Miller B; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Labaudiniere R; Huang F; Djuric SW
    Bioorg Med Chem Lett; 1998 Nov; 8(21):3053-8. PubMed ID: 9873675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
    Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
    J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors.
    Rhee CK; Kim JH; Suh BC; Xiang MX; Youn YS; Bang WY; Kim E; Shin JK; Lee Y
    Arch Pharm Res; 1999 Apr; 22(2):202-7. PubMed ID: 10230513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
    Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.